Breast Imaging-Reporting and Data System (BI-RADS) classification in 51 excised palpable pediatric breast masses

Jeffrey L Koning1, Katherine P Davenport2, Patricia S Poole3

  • 1Department of Radiology, University of California San Diego, 200 West Arbor Drive MC 8756, San Diego, CA 92103-8756, United States.

Insights

The Breast Imaging Reporting and Data System (BI-RADS) classification may not accurately assess malignancy risk in pediatric breast masses. In this study, all BI-RADS 4 lesions in children were benign, suggesting potential overestimation of risk.

Area of Science:

  • Radiology
  • Pediatric Surgery
  • Oncology

Background:

  • The American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) is used for breast lesion risk stratification.
  • Previous BI-RADS validation studies have not included pediatric populations.
  • Pediatric breast masses often present as palpable lesions and are evaluated with ultrasound, frequently receiving a BI-RADS classification.

Purpose of the Study:

  • To correlate BI-RADS classifications with histopathological findings in pediatric breast masses.
  • To assess the applicability and accuracy of the BI-RADS classification system in pediatric patients.

Main Methods:

  • Retrospective review of pediatric patients (n=105) who underwent breast mass excision from July 2010 to November 2013.
  • Analysis of preoperative ultrasound BI-RADS classifications (n=51) and correlation with surgical pathology.
  • Inclusion of demographic data and imaging results.

Main Results:

  • 119 palpable masses were excised from 105 pediatric patients.
  • Of 51 masses with BI-RADS classification, all were in female patients (average age 15.9 years).
  • 25 masses (49%) were classified as BI-RADS 4, and 100% of these demonstrated benign pathology, most commonly fibroadenoma.

Conclusions:

  • The BI-RADS classification may not be a valid treatment algorithm for pediatric breast lesions.
  • BI-RADS 4 classification in pediatric patients in this cohort did not correlate with malignancy.
  • Further large-scale studies are needed to validate BI-RADS in pediatric and adolescent populations to avoid overstating malignancy risk or the need for biopsy.
Abstract

Related Concept Videos